1 reports of this reaction
4.2% of all TITANIUM DIOXIDE, ZINC OXIDE reports
#4 most reported adverse reaction
APPLICATION SITE ERYTHEMA is the #4 most commonly reported adverse reaction for TITANIUM DIOXIDE, ZINC OXIDE, manufactured by Edgewell Personal Care Brands LLC. There are 1 FDA adverse event reports linking TITANIUM DIOXIDE, ZINC OXIDE to APPLICATION SITE ERYTHEMA. This represents approximately 4.2% of all 24 adverse event reports for this drug.
Patients taking TITANIUM DIOXIDE, ZINC OXIDE who experience application site erythema should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
APPLICATION SITE ERYTHEMA is moderately reported among TITANIUM DIOXIDE, ZINC OXIDE users, representing a notable but not dominant share of adverse events.
In addition to application site erythema, the following adverse reactions have been reported for TITANIUM DIOXIDE, ZINC OXIDE:
The following drugs have also been linked to application site erythema in FDA adverse event reports:
APPLICATION SITE ERYTHEMA has been reported as an adverse event in 1 FDA reports for TITANIUM DIOXIDE, ZINC OXIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
APPLICATION SITE ERYTHEMA accounts for approximately 4.2% of all adverse event reports for TITANIUM DIOXIDE, ZINC OXIDE, making it a notable side effect.
If you experience application site erythema while taking TITANIUM DIOXIDE, ZINC OXIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.